Infinity Pharmaceuticals Inc.
780 Memorial Drive
About Infinity Pharmaceuticals Inc.The mission of Infinity Pharmaceuticals, Inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation.
Small molecule discovery and development capabilities Infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation.
Strategic alliances Building on its strengths in innovative small molecule drug discovery and development, Infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline.
Business and scientific expertise The company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business and drug discovery and development.
Culture of Citizen-Ownership Infinity’s culture and environment of Citizen-Ownership is as important as its technologies. Infinity works together as a community with the shared goal of bringing important new medicines to patients.
400 articles with Infinity Pharmaceuticals Inc.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced two poster presentations featuring clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) at the upcoming San Antonio Breast Cancer Symposium (SABCS) being held virtually, December 8-11, 2020. Presentation Details: Title: MARIO-3 phase II study initial data evaluating a novel triplet combination of e
– MARIO-275 IDMC Determined that Risk/Benefit for Patients Warrants Resumption of Enrollment; Infinity to Determine Next Steps by Year End – – MARIO-3 Encouraging Data in Front-Line Triple Negative Breast Cancer Patients to be Presented at San Antonio Breast Cancer Symposium – – MARIO-1 Melanoma and SCCHN Data Presented at SITC – – Cash Runway Through 2021 –
Infinity Pharmaceuticals Presents New MARIO-1 Phase 1/1b Clinical Data at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
– Data from melanoma and SCCHN cohorts demonstrate eganelisib was well tolerated in combination with Opdivo ® – - Translational data supports on-mechanism immune modulation - - Clinical activity in patients with two or fewer prior lines of therapy validates Infinity’s clinical strategy advancing eganelisib to earlier treatment settings –
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), will host a conference call on November 9, 2020 at 4:30 p.m. ET to report its financial results for the third quarter ended September 30, 2020 and provide an update on the company.
Infinity Receives Fast Track Designation for Eganelisib in Combination with a Checkpoint Inhibitor and Chemotherapy for First-Line Treatment of Advanced TNBC
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for eganelisib (IPI-549) in combination with a checkpoint inhibitor and chemotherapy for the treatment of patients with inoperable locally advanced or metastatic triple-negative breast cancer (TNBC), in the first-line setting. Infinity is currently enrolling patients in MAR
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), today announced that management will be participating in the following investor conferences this month: Wells Fargo Securities Annual Healthcare Conference Da
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2020 financial results and provided an update on the company, including its second quarter progress with eganelisib (also known as IPI-549), the company’s first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibition.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on July 30, 2020 at 4:30 p.m. ET to review its second quarter 2020 financial results and provide an update on the company. A live webcast of the conference call can be accessed in the Investors/Media section of Infinity's website at www.infi.com . To participate in the conference call, please dial (877) 316-5293 (domestic) and (631) 291-45
The date and time of the 2020 Annual Meeting remain 8:30 a.m. ET on June 17, 2020 – – To participate in the virtual meeting, stockholders must register by 11:59 ET on June 15, 2020 –
Fast Track Designation Granted for IPI-549 Plus Opdivo ® in Patients with Advanced Urothelial Cancer – – Infinity Voluntarily Pausing Enrollment on MARIO-275 to Evaluate the Risk/Benefit for Patients – – Completion of Enrollment for MARIO-275 and MARIO-3 Delayed with Outlook for Completion of Enrollment and Impact on Data Readouts to Be Updated by 2Q Earnings Webcast – – $20M Asset Backed Financing with BVF in January; Cash Runway into
Infinity Pharmaceuticals, Inc. will host a conference call on Monday, May 11, 2020 at 4:30 p.m. ET to review its first quarter 2020 financial results and provide an update on the company.
Infinity Pharmaceuticals, Inc. provided an update in response to the COVID-19 pandemic.
Infinity Receives Fast Track Designation for IPI-549 in Combination with the Checkpoint Inhibitor Opdivo for the Treatment of Advanced Urothelial Cancer
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IPI-549 in combination with nivolumab (Opdivo®) for the treatment of advanced urothelial cancer.
Infinity Pharmaceuticals, Inc . (NASDAQ: INFI) announced today the appointment of Richard Gaynor, M.D. to its Board of Directors, effective March 16, 2020. “We are thrilled to have Dr. Gaynor join the board as we advance IPI-549 to important data readouts,” said Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals. “Richard’s tremendous expertise, first as a practicing academic oncologis
Enrollment Completion for MARIO-275, Infinity’s Global, Randomized Phase 2 Study in Patients with Urothelial Cancer, Expected in 2020 with Data Expected in 2021
Infinity Announces the Date of Its Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, March 3, 2020 at 4:30 p.m. ET to review its fourth quarter and full year 2019 financial results and provide an update on the company.
Infinity Pharmaceuticals Inc. (NASDAQ: INFI) today announced 2020 milestones for IPI-549, a first-in-class, oral, immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibition and provided financial guidance for 2020.
Infinity Pharmaceuticals Raises $20 Million Through an Innovative Non-Dilutive Asset-Backed Financing from BVF
Infinity Pharmaceuticals, Inc. announced a $20 million non-dilutive asset-backed financing with BVF Partners L.P., Infinity’s largest shareholder.
Infinity Pharmaceuticals to Present Corporate Overview at 38th Annual J.P. Morgan Global Healthcare Conference
Infinity Pharmaceuticals, Inc. announced that Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals, will provide a corporate overview at the 38th Annual J.P. Morgan Global Healthcare Conference on Thursday, January 16, 2020 at 9:00 am Pacific Time at the Westin St. Francis Hotel in San Francisco, California.
Infinity Pharmaceuticals, Inc. announced its third quarter 2019 financial results and provided an update on the company, including its progress with IPI-549, a first-in-class oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma inhibition..